Jordi Codony‐Servat

Author

Jordi Codony‐Servat

Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol ORCID

Also Known As

J Codony-Servat, J. Codony-Servat, Jordi Codony-Servat, Jordi Codony‐Servat

111

Publications

3.4K

Citations

H-Index

Concepts

All Affiliations

Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol Institut Català d'Oncologia Instituto Oncológico Dr. Rosell USP Institut Universitari Dexeus Consorci Institut D'Investigacions Biomediques August Pi I Sunyer

About

Jordi Codony‐Servat is an author at Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol specializing in medicine, cancer research, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	1.6K
2	Cell Biology	6	6	1.5K
3	Engineering	1	1	116
4	Natural Sciences	1	1	775
5	Biochemistry	1	1	775

Jordi Codony‐Servat

Publications

2.9K

Citations

H-Index

Page 1

	Year	Citations
Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Jordi Codony‐Servat, Joan Albanell, Federico Rojo, PubMed Her2 Ectodomain CleavageBreast OncologyBiochemistryMedicineNatural Sciences	2001	775
Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Joan Albanell, Jordi Codony‐Servat, Federico Rojo, PubMed Epidermal Growth FactorExtracellular Signal-regulated KinasesPathologyNeck Squamous CarcinomaGrowth Factor Alpha	2001	275
Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Jordi Codony‐Servat, Joan Albanell, Juan Carlos López-Talavera, PubMed Breast OncologyMolecular BiologyCancer BiologyTumor BiologySignaling Pathway	1999	238
Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer Kirstine Jacobsen, Jordi Bertrán-Alamillo, Miguel Ángel Molina‐Vila, Nature Communications	2017	181
Interleukin 6, a Nuclear Factor-κB Target, Predicts Resistance to Docetaxel in Hormone-Independent Prostate Cancer and Nuclear Factor-κB Inhibition by PS-1145 Enhances Docetaxel Antitumor Activity Josep Domingo‐Domenech, Cristina Oliva, Ana Rovira, Clinical Cancer Research	2006	169
Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate Cancer Mercedes Marín‐Aguilera, Jordi Codony‐Servat, Òscar Reig, Molecular Cancer Therapeutics	2014	147
AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy Jordi Bertrán-Alamillo, Valérie Cattan, Marie Schoumacher, Nature Communications	2019	144
Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer Mercedes Marín‐Aguilera, Jordi Codony‐Servat, Susana G. Kalko, Molecular Cancer Therapeutics EngineeringGeneticsCancer BiologyTumor BiologyDrug Resistance	2011	116
Activation of nuclear factor-κB in human prostate carcinogenesis and association to biochemical relapse Josep Domingo‐Domenech, Begoña Mellado, David Truan, British Journal of Cancer	2005	113
Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells Jordi Codony‐Servat, M. Tapia, Marta Bosch, Molecular Cancer Therapeutics	2006	106

Page 1